Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefiting from an intensification of chemotherapy, which is a major prognostic factor in this population.

Trial Details

NCT ID
NCT04602377
Phase
PHASE2
Sponsor
ARCAGY/ GINECO GROUP
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Pembrolizumab 25 MG/ML [Keytruda]
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Angers, France|47.47156,-0.55202
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046
  • Dijon, France|47.31344,5.01391

Key Eligibility Criteria

  • Patient who are at least 12 years of age on the day of signing informed consent with previously untreated, pathologically confirmed Small cell carc…
  • Stage FIGO I to IV classification
  • Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Have adequate organ function:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →